- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 23, 2014
Highlights
- Year Range
- $0.80 - $1.85
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
APTOF Performance Chart
Aptose Biosciences Inc (APTOF) is up 0.0% since the beginning of the year. At $1 per share, APTOF is trading 20.0% below its 52-week high of $2. Investors who bought $1,000 worth of APTOF shares 5 years ago would now be looking at an investment worth $1.
Loading charts...
Returns By Period
Aptose Biosciences Inc (APTOF) has returned -0.00% so far this year and 53.83% over the past 12 months. Over the last ten years, APTOF has returned -48.08% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Aptose Biosciences Inc
- 1D
- -5.13%
- 1M
- -13.15%
- YTD
- -0.00%
- 6M
- -2.57%
- 1Y
- 53.83%
- 3Y*
- -79.30%
- 5Y*
- -74.96%
- 10Y*
- -48.08%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
APTOF Monthly Returns History
Based on dividend-adjusted daily data since Oct 23, 2014, APTOF's average daily return is -0.10%, while the average monthly return is -2.70%.
Historically, 41% of months were positive and 59% were negative. The best month was Dec 2019 with a return of +109.2%, while the worst month was Nov 2024 at -52.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 8 months.
On a daily basis, APTOF closed higher 42% of trading days. The best single day was Mar 24, 2021 with a return of +66.2%, while the worst single day was Nov 20, 2015 at -52.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 13.51% | -7.14% | 6.79% | 3.24% | -4.07% | -10.30% | -0.00% | ||||||
| 2025 | -21.88% | -39.58% | -1.25% | -35.56% | -16.26% | -48.95% | 48.65% | -2.33% | -7.14% | 13.68% | 24.81% | -10.84% | -78.10% |
| 2024 | -21.26% | -10.00% | -7.78% | -27.71% | -18.75% | -22.15% | -25.31% | -28.38% | 1.21% | -7.35% | -52.72% | 25.17% | -91.13% |
| 2023 | 29.31% | -22.40% | 9.97% | -24.58% | -15.06% | -24.55% | -33.19% | 30.65% | -30.86% | -0.36% | -12.54% | 4.10% | -70.80% |
| 2022 | -3.70% | -7.69% | 13.33% | -12.50% | -15.13% | -26.52% | 0.00% | 5.38% | -23.91% | -22.61% | 44.41% | -12.78% | -57.04% |
| 2021 | -5.94% | -3.88% | 50.88% | -5.61% | -6.03% | -37.36% | -18.98% | 11.15% | -27.09% | -5.96% | 7.32% | -38.64% | -69.18% |
Benchmark Metrics
Aptose Biosciences Inc has an annualized alpha of -30.00%, beta of 0.77, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since October 23, 2014.
- This stock participated in 198.11% of S&P 500 Index downside but only -59.41% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -30.00%
- Beta
- 0.77
- R²
- 0.02
- Upside Capture
- -59.41%
- Downside Capture
- 198.11%
Return for Risk
Risk / Return Rank
APTOF ranks 69 for risk / return — better than 69% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Aptose Biosciences Inc (APTOF) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| APTOF | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.38 | ||
| Sortino ratioReturn per unit of downside risk | -0.95 | ||
| Omega ratioGain probability vs. loss probability | 1.25 | 1.37 | -0.12 |
| Calmar ratioReturn relative to maximum drawdown | 1.19 | 2.78 | -1.59 |
| Martin ratioReturn relative to average drawdown | 2.60 | 12.44 | -9.84 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Aptose Biosciences Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Aptose Biosciences Inc was 99.98%, occurring on Jun 25, 2025. The portfolio has not yet recovered.
The current Aptose Biosciences Inc drawdown is 99.96%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -99.98%Jun 2025 | 5y 4mo | — | 6y 4moFeb 2020 - now |
2017 bear market2017 | -89.68%Apr 2017 | 2y 5mo | 2y 9mo | 5y 3moOct 2014 - Feb 2020 |
2014 pullback2014 | -4.71%Oct 2014 | 0s | 1d | 1dOct 2014 - Oct 2014 |
Drawdown Indicators
| APTOF | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.98% | -56.78% | -43.20% |
Max Drawdown (1Y)Largest decline over 1 year | -45.41% | -9.10% | -36.31% |
Max Drawdown (3Y)Largest decline over 3 years | -99.52% | -18.90% | -80.62% |
Max Drawdown (5Y)Largest decline over 5 years | -99.95% | -25.43% | -74.52% |
Max Drawdown (10Y)Largest decline over 10 years | -99.98% | -33.92% | -66.06% |
Current DrawdownCurrent decline from peak | -99.96% | -1.80% | -98.16% |
Average DrawdownAverage peak-to-trough decline | -72.51% | -10.71% | -61.80% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.86% | 2.03% | +18.83% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Aptose Biosciences Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Aptose Biosciences Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with APTOF
Add Aptose Biosciences Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with APTOF